MAPT and neuroblastoma: In line with previous studies in neuroblastoma cells [37], application of WZ4003 resulted in a significant, and largely proportional, reduction in both total tau (Fig. 4c, effect of treatment: *F(1,51.00) = 7.01, p = 0.011) and p-tau Ser356 (Fig. 4d, effect of treatment: **F(1,51.00) = 10.7, p = 0.002) (Fig. 4e, effect of treatment on p-tau Ser356/total tau ratio: F(1,51.00) = 2.10, p = 0.15).